Gene therapy for pulmonary hypertension: Prospects and challenges

Expert Opinion on Biological Therapy

Volumn 11, Issue 2, 2011, Pages 133-143

  Reynolds, Paul N ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

BMPR2; gene therapy; pulmonary hypertension; pulmonary vasculature

Indexed keywords

ADENOVIRUS VECTOR; ADRENOMEDULLIN; ANGIOPOIETIN 1; ANTISENSE OLIGONUCLEOTIDE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 EPOXYGENASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR ANTAGONIST; EXTRACELLULAR SUPEROXIDE DISMUTASE; IMATINIB; MICRORNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9B9; OXIDOREDUCTASE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; POTASSIUM CHANNEL KV1.5; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; PROTEIN INHIBITOR; RIOCIGUAT; SCATTER FACTOR; SURVIVIN INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANTIHYPERTENSIVE THERAPY; CYTOKINE RESPONSE; DRUG DISTRIBUTION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE VECTOR; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HUMAN; LUNG TRANSPLANTATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PATHOGENESIS; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; GENE THERAPY; HUMANS; HYPERTENSION, PULMONARY;

ANIMALIA;

EID: 78651369037     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.542139     Document Type: Review

References (85)

1. Lee SD, Shroyer KR, Markham NE, et al Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998;101:927-34
2. Tuder RM. Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009;30:376-85
3. Badesch DB, Champion HC, Sanchez MA, et al Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S55-66
4. Lane KB, Machado RD, Pauciulo MW, et al Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-4
5. Machado RD, Pauciulo MW, Thomson JR, et al BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001;68:92-102
6. Simonneau G, Robbins IM, Beghetti M, et al Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43-54
7. Newman JH, Wheeler L, Lane KB, et al Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319-24
8. Deng Z, Morse JH, Slager SL, et al Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-44
9. Humbert M, Sitbon O, Chaouat A, et al Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30
10. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81
11. Sitbon O, Humbert M, Jais X, et al Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11
12. Barst RJ, Gibbs JS, Ghofrani HA, et al Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S78-84
13. Barst RJ, Rubin LJ, Long WA, et al A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302
14. McLaughlin VV, Sitbon O, Badesch DB, et al Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9
15. Rubin LJ, Badesch DB, Barst RJ, et al Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
16. Galie N, Ghofrani HA, Torbicki A, et al Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
17. Olschewski H, Simonneau G, Galie N, et al Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
18. McLaughlin VV, Suissa S. Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. Circulation 2010;122:106-8
19. Humbert M, Sitbon O, Chaouat A, et al Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63
20. Benza RL, Miller DP, Gomberg-Maitland M, et al Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72
21. Ghofrani HA, Morrell NW, Hoeper MM, et al Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-7
22. Ghofrani HA, Hoeper MM, Halank M, et al Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-9
23. Harrison RE, Flanagan JA, Sankelo M, et al Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003;40:865-71
24. Machado RD, Eickelberg O, Elliott CG, et al Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S32-42
25. Upton PD, Morrell NW. TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases. Curr Opin Pharmacol 2009;9:274-80
26. Long L, Crosby A, Yang X, et al Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009;119:566-76
27. Atkinson C, Stewart S, Upton PD, et al Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672-8
28. Austin ED, Phillips JA, Cogan JD, et al Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res 2009;10:87
29. Sztrymf B, Coulet F, Girerd B, et al Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008;177:1377-83
30. Frank DB, Abtahi A, Yamaguchi DJ, et al Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res 2005;97:496-504
31. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al Bone morphogenetic proteinreceptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 2006;98:209-17
32. Stewart DJ. Bone morphogenetic protein receptor-2 and pulmonary arterial hypertension: unraveling a riddle inside an enigma? Circ Res 2005;96:1033-5
33. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-38
34. Hong KH, Lee YJ, Lee E, et al Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 2008;118:722-30
35. Arciniegas E, Frid MG, Douglas IS, et al Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007;293:L1-8
36. Zeisberg EM, Tarnavski O, Zeisberg M, et al Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952-61
37. Frank DB, Lowery J, Anderson L, et al Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol 2008;294:L98-109
38. Lowery JW, de Caestecker MP. BMP signaling in vascular development and disease. Cytokine Growth Factor Rev 2010;21:287-98
39. West J, Harral J, Lane K, et al Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 2008;295:L744-755
40. Song Y, Jones JE, Beppu H, et al Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005;112:553-62
41. Hagen M, Fagan K, Steudel W, et al Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 2007;292:L1473-1479
42. Nagaya N, Yokoyama C, Kyotani S, et al Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 2000;102:2005-10
43. Rodman DM, San H, Simari R, et al In vivo gene delivery to the pulmonary circulation in rats: transgene distribution and vascular inflammatory response. Am J Respir Cell Mol Biol 1997;16:640-9
44. Curiel DT. High-efficiency gene transfer mediated by adenovirus- polylysine-DNA complexes. Ann N Y Acad Sci 1994;716:36-56; discussion 56-8
45. Bergelson JM, Cunningham JA, Droguett G, et al Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3
46. Waddington SN, McVey JH, Bhella D, et al Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008;132:397-409
47. Reynolds PN. Delivery of DNA to pulmonary endothelium using adenoviral vectors. Methods Mol Biol 2004;246:69-89
48. Danilov SM, Muzykantov VR, Martynov AV, et al Lung is the target organ for a monoclonal antibody to angiotensin-converting enzyme. Lab Invest 1991;64(1):118-24
49. Orte C, Polak JM, Haworth SG, et al Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 2000;192:379-84
50. Giordano RJ, Edwards JK, Tuder RM, et al Combinatorial ligand-directed lung targeting. Proc Am Thorac Soc 2009;6:411-15
51. Reynolds PN, Zinn KR, Gavrilyuk VD, et al A targetable injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2000;2:562-78
52. Alba R, Bradshaw AC, Parker AL, et al Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009;114:965-71
53. Alba R, Bradshaw AC, Coughlan L, et al Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010;116:2656-64
54. Everts M, Kim-Park SA, Preuss MA, et al Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors. Gene Ther 2005;12:1042-8
55. Izumi M, Kawakami Y, Glasgow JN, et al In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. J Gene Med 2005;7:1517-25
56. Nicklin SA, Reynolds PN, Brosnan MJ, et al Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 2001;38:65-70
57. Reynolds PN, Nicklin SA, Kaliberova L, et al Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001;19:838-42
58. McMurtry MS, Moudgil R, Hashimoto K, et al Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007;292:L872-878
59. Pickles RJ, Fahrner JA, Petrella JM, et al Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J Virol 2000;74:6050-7
60. Griesenbach U, Alton EW. Cystic fibrosis gene therapy: successes, failures and hopes for the future. Expert Rev Respir Med 2009;3:363-71
61. Tahara N, Kai H, Niiyama H, et al Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum Gene Ther 2004;15:1270-8
62. Suhara H, Sawa Y, Fukushima N, et al Gene transfer of human prostacyclin synthase into the liver is effective for thetreatment of pulmonary hypertension in rats. J Thorac Cardiovasc Surg 2002;123:855-61
63. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006;13:1031-49
64. Romano G, Marino IR, Pentimalli F, et al Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients. Drug News Perspect 2009;22:185-96
65. Brunetti-Pierri N, Ng P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther 2008;15:553-60
66. Flynn R, Buckler JM, Tang C, et al Helper-dependent adenoviral vectors are superior in vitro to first-generation vectors for endothelial cell-targeted gene therapy. Mol Ther 2010: published online 31 August 2010, doi:10.1038/mt.2010.176
67. McMurtry MS, Archer SL, Altieri DC, et al Gene therapy targeting surviving selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-91
68. Zhao YD, Campbell AI, Robb M, et al Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 2003;92:984-91
69. Jurasz P, Courtman D, Babaie S, et al Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials. Pharmacol Ther 2010;126:1-8
70. Zhao YD, Courtman DW, Deng Y, et al Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96:442-50
71. Yip HK, Chang LT, Sun CK, et al Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats. Crit Care Med 2008;36:873-80
72. Sueblinvong V, Weiss DJ. Cell therapy approaches for lung diseases: current status. Curr Opin Pharmacol 2009;9:268-73
73. Takemiya K, Kai H, Yasukawa H, et al Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol 2010;105:409-17
74. Kanki-Horimoto S, Horimoto H, Mieno S, et al Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 2006;114(1 Suppl):I181-5
75. Reynolds AM, Holmes M, Morrell NW, et al Gene delivery of bone morphogenetic protein receptor type-2 attenuates established hypoxic and monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 2010;181:A6333
76. Reynolds AM, Xia W, Holmes MD, et al Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007;292:L1182-92
77. Vieillard-Baron A, Frisdal E, Raffestin B, et al Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Hum Gene Ther 2003;14:861-9
78. Pozeg ZI, Michelakis ED, McMurtry MS, et al In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003;107:2037-44
79. Zheng C, Wang L, Li R, et al Gene delivery of a cytochrome P450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. Am J Respir Cell Mol Biol 2010: published online 29 January 2010, doi:10.1165/rcmb.2009-0161OC
80. Harada-Shiba M, Takamisawa I, Miyata K, et al Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats. Mol Ther 2009;17:1180-6
81. Farkas L, Farkas D, Ask K, et al VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009;119:1298-311
82. Kamezaki F, Tasaki H, Yamashita K, et al Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2008;177:219-26
83. Ono M, Sawa Y, Fukushima N, et al Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats. Eur J Cardiothorac Surg 2004;26:1092-7
84. Vieillard-Baron A, Frisdal E, Eddahibi S, et al Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res 2000;87:418-25
85. Morse J, Barst R, Horn E, et al Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002;29:2379-81